Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Aimmune’s Prospects Shine After the FDA Approves Its Allergy Drug

By Chris Lau, InvestorPlace Contributor

Aimmune Therapeutics received FDA approval for its peanut allergy drug Palforzia, and AIMT stock could soar in 2020.

What to Expect From General Electric as Its Turnaround Accelerates

By Chris Lau, InvestorPlace Contributor

General Electric is clearly in the midst of a big turnaround, and GE stock is looking like a great stock to buy now.

Here’s What Aphria Needs to Reward Investors With 41% Upside

By Chris Lau, InvestorPlace Contributor

If you are willing to hold Aphria stock for at least three years before selling, buy some shares now to make a bet on its upside potential.

7 Festive Stocks to Buy for Chinese New Year Celebrations

By Chris Lau, InvestorPlace Contributor

Despite coronavirus fears weighing on Chinese stocks, these seven companies are great stocks to buy for the year of the rat.

Apple Has Plenty of Upside Left Thanks to Its Upcoming 5G Models

By Chris Lau, InvestorPlace Contributor

Apple reported stellar first quarter earnings, including an all-time record revenue number. Apple stock looks like a long-term buy now.

Load More